Product Details
Materials Provided
IDComponentsSizeEP137-C01High-bind Plate1 plateEP137-C02Human VEGFA10 μgEP137-C03Biotinylated Human VEGFR220 μgEP137-C04Anti-VEGFA Neutralizing Antibody20 μgEP137-C05Streptavidin-HRP10 μgEP137-C06Coating Buffer12 mLEP137-C0710xWashing Buffer50 mLEP137-C08Blocking Buffer50 mLEP137-C09Substrate Solution12 mLEP137-C10Stop Solution7 mLProduct Overview
VEGFA : VEGFR2 [Biotinylated] Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human VEGFA binding to human VEGFR2. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human VEGFA binding to human VEGFR2.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.

INHIBITION OF VEGFA: VEGFR2 [Biotinylated] BINDING BY ANTI-VEGF NEUTRALIZING ANTIBODY
Serial dilutions of Anti-VEGFA Neutralizing antibody (Catalog # EP137-C04) (1:1 serial dilution, from 10 μg/mL to 0.15625 μg/mL) was added into VEGFA: Biotinylated VEGFR2 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Customer Reviews Writing Reviews

Recent Advances
- English Name:
Vascular endothelial growth factor A
- Category:
- Approved Drugs:
54 Details
- Drugs in Clinical Trials:
61 Details
- Highest Development Stage:
Approved
メールアドレス
order.jp@acrobiosystems.comお問い合わせ
グローバル:+1 800-810-0816(Toll Free)



















